| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-08-1258 |
| P698 | PubMed publication ID | 19118056 |
| P50 | author | Jacek Niklinski | Q11715481 |
| Witold Rzyman | Q115110026 | ||
| Jacek Jassem | Q19690551 | ||
| Giuseppe Giaccone | Q37829946 | ||
| Nico van Zandwijk | Q37838131 | ||
| Marcin Skrzypski | Q80002122 | ||
| P2093 | author name string | Egbert F Smit | |
| Michael Meister | |||
| Paul Roepman | |||
| Thomas Muley | |||
| Wolter J Mooi | |||
| Hendrik Dienemann | |||
| Arno Floore | |||
| Miroslaw Kozlowski | |||
| Tony van de Velde | |||
| Sjaak Burgers | |||
| Anke T Witteveen | |||
| P2860 | cites work | Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma | Q23916642 |
| A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. | Q34555834 | ||
| P433 | issue | 1 | |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 284-290 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer | |
| P478 | volume | 15 |
| Q36746536 | A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients |
| Q61917168 | A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer |
| Q52629098 | A Risk Stratification Model for Lung Cancer Based on Gene Coexpression Network and Deep Learning. |
| Q92652655 | A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer |
| Q36055512 | A lung cancer molecular prognostic test ready for prime time |
| Q38381789 | A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. |
| Q88657584 | A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients |
| Q35803022 | A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies |
| Q28731800 | A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients |
| Q36494964 | A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency |
| Q33483366 | A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors |
| Q35200402 | Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? |
| Q89985645 | CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome prediction |
| Q33562564 | CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. |
| Q28396195 | Cancer research: from prognostic genes to therapeutic targets |
| Q30235944 | Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies |
| Q34412292 | Development and validation of a prognostic gene-expression signature for lung adenocarcinoma |
| Q35197454 | Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. |
| Q37702094 | Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers |
| Q35680083 | EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. |
| Q28388842 | Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma |
| Q33611881 | Gene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC. |
| Q28395058 | Gene expression-based classification of non-small cell lung carcinomas and survival prediction |
| Q33988433 | Gene expression-based prognostic signatures in lung cancer: ready for clinical use? |
| Q47130427 | Generating a robust prediction model for stage I lung adenocarcinoma recurrence after surgical resection |
| Q37153528 | Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients |
| Q31075558 | High-dimensional genomic data bias correction and data integration using MANCIE |
| Q28396184 | Highlight report: Validation of prognostic genes in lung cancer |
| Q35146944 | How close are we to customizing chemotherapy in early non-small cell lung cancer? |
| Q64979256 | Identification of an early diagnostic biomarker of lung adenocarcinoma based on co-expression similarity and construction of a diagnostic model. |
| Q95661071 | Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data |
| Q60375472 | Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms |
| Q34586327 | Immune regulation of cancer |
| Q50234294 | Immunomodulation of breast cancer via tumor antigen specific Th1. |
| Q35644193 | Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells |
| Q40629175 | Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. |
| Q35561695 | Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer |
| Q37254004 | Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung |
| Q64947321 | Large-scale gene expression analysis reveals robust gene signatures for prognosis prediction in lung adenocarcinoma. |
| Q28387769 | Lung Cancer Gene Signatures and Clinical Perspectives |
| Q24632760 | Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types |
| Q38107464 | Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis |
| Q44582343 | Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms |
| Q42378386 | NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer. |
| Q37564046 | Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients |
| Q38373627 | Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. |
| Q96303706 | OSluca: An Interactive Web Server to Evaluate Prognostic Biomarkers for Lung Cancer |
| Q28394867 | Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy |
| Q64263796 | Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data |
| Q30497419 | Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer |
| Q28394974 | Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer |
| Q35022194 | Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the Eur |
| Q41457800 | Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers |
| Q51557016 | Signaling protein signature predicts clinical outcome of non-small-cell lung cancer. |
| Q36407448 | Sparse principal component analysis in cancer research |
| Q35212682 | T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival |
| Q91872237 | T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer |
| Q35124700 | The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine |
| Q28383695 | The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts |
| Q41992713 | The peripheral immune response and lung cancer prognosis |
| Q35667675 | The role of gene expression profiling in early-stage non-small cell lung cancer |
| Q35193892 | Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept |
| Q33655234 | Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. |
| Q36710911 | Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients |
| Q30830295 | Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma |
| Q21133557 | When is hub gene selection better than standard meta-analysis? |
| Q28385778 | Yin Yang gene expression ratio signature for lung cancer prognosis |
Search more.